Edition:
India

Adial Pharmaceuticals Inc (ADIL.OQ)

ADIL.OQ on NASDAQ Stock Exchange Capital Market

2.23USD
30 Sep 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.23
Open
--
Day's High
--
Day's Low
--
Volume
117
Avg. Vol
296,641
52-wk High
$4.00
52-wk Low
$1.00

Latest Key Developments (Source: Significant Developments)

Adial Pharmaceuticals And Biolab Sciences Enter Into Distribution Agreement For Covid-19 Antibody Tests
Monday, 8 Jun 2020 

June 8 (Reuters) - Adial Pharmaceuticals Inc ::ADIAL PHARMACEUTICALS AND BIOLAB SCIENCES ENTER INTO DISTRIBUTION AGREEMENT FOR COVID-19 ANTIBODY TESTS.ADIAL PHARMACEUTICALS INC - ANTIBODY TESTING AVAILABLE FOR LANDMARK ONWARD PIVOTAL PHASE 3 TRIAL PARTICIPANTS.ADIAL PHARMACEUTICALS - BIOLAB SCIENCES GRANTS ADIAL EXCLUSIVE RIGHTS TO SELL AND DISTRIBUTE RAPID RESULT COVID-19 ANTIBODY TESTS TO DESIGNATED CHANNEL PARTNERS.  Full Article

Adial Pharmaceuticals Inc says On May 26, Reached Understanding On Terms To Purchase Covid-19 IgG / IgM Rapid Test Kits
Wednesday, 27 May 2020 

May 27 (Reuters) - Adial Pharmaceuticals Inc ::ADIAL PHARMACEUTICALS INC - ON MAY 26, REACHED UNDERSTANDING ON TERMS TO PURCHASE COVID-19 IGG / IGM RAPID TEST KITS.ADIAL PHARMACEUTICALS - INTENDS TO TEST PARTICIPANTS IN ITS LANDMARK ONWARD!" PIVOTAL PHASE 3 CLINICAL TRIAL OF CO'S LEAD DRUG CANDIDATE, AD04.ADIAL - INTENDS TO TEST PARTICIPANTS IN PHASE 3 TRIAL OF AD04, FOR TREATMENT OF ALCOHOL USE DISORDER TO IMPROVE SAFETY, ENHANCE TRIAL RETENTION RATES.  Full Article

Adial Pharmaceuticals Announces Modifications To Phase 3 Pivotal Trial Of Ad04 To Protect Subjects From Covid-19
Tuesday, 17 Mar 2020 

March 17 (Reuters) - Adial Pharmaceuticals Inc ::ADIAL PHARMACEUTICALS INC. - ADIAL PHARMACEUTICALS ANNOUNCES MODIFICATIONS TO PHASE 3 PIVOTAL TRIAL OF AD04 TO PROTECT SUBJECTS FROM COVID-19.ADIAL PHARMACEUTICALS - IN PROCESS OF MODIFYING PROTOCOL TO REDUCE NO. OF IN-PERSON VISITS TO CLINICAL SITES.ADIAL PHARMACEUTICALS INC - DURATION OF IN-PERSON VISITS IS BEING REDUCED THROUGH REMOVAL OF NON-ESSENTIAL ASSESSMENTS.  Full Article

Adial Pharmaceuticals Receives Approval To Commence Phase 3 Trial In Finland
Thursday, 9 Jan 2020 

Jan 9 (Reuters) - Adial Pharmaceuticals Inc ::ADIAL PHARMACEUTICALS INC - RECEIVES APPROVAL TO COMMENCE PHASE 3 STUDY TO INVESTIGATE AD04 FOR TREATMENT OF ALCOHOL USE DISORDER IN FINLAND.  Full Article

Adial Says Entered Into Amendment No. 7 To License Agreement With University Of Virginia Patent Foundation
Wednesday, 1 Jan 2020 

Dec 31 (Reuters) - Adial Pharmaceuticals Inc ::ADIAL PHARMACEUTICALS INC - ON DECEMBER 31, ENTERED INTO AMENDMENT NO. 7 TO LICENSE AGREEMENT WITH UNIVERSITY OF VIRGINIA PATENT FOUNDATION.ADIAL PHARMACEUTICALS INC - AMENDMENT NO. 7 REMOVED IN ITS ENTIRETY DILIGENCE MILESTONE TO INITIATE A PHASE 3 CLINICAL TRIAL BY DECEMBER 31, 2019.ADIAL PHARMACEUTICALS - CO TO PAY UPON EXECUTION OF AMENDMENT NO. 7, PAYMENT OF $20,000 THAT HAD BEEN DUE UPON INITIATION OF A PHASE 3 CLINICAL TRIAL.ADIAL PHARMACEUTICALS - EXPECTS TO DOSE A FIRST PATIENT WITH A LICENSED PRODUCT IN A PHASE 3 CLINICAL TRIAL ON OR BEFORE MARCH 31, 2020.  Full Article

Adial Files Clinical Trial Application To Commence Phase 3 Trial
Tuesday, 1 Oct 2019 

Adial Pharmaceuticals Inc ::ADIAL FILES CLINICAL TRIAL APPLICATION TO COMMENCE PHASE 3 TRIAL.ADIAL PHARMACEUTICALS - SUBMITTED APPLICATION TO COMMENCE PHASE 3 CLINICAL TRIAL OF AD04 FOR TREATMENT OF ALCOHOL USE DISORDER WITH SWEDISH AGENCY.  Full Article

Adial Pharmaceuticals - Submits Continuation Patent Application For Use Of AD04
Friday, 15 Feb 2019 

Feb 15 (Reuters) - Adial Pharmaceuticals Inc ::ADIAL PHARMACEUTICALS - SUBMITS CONTINUATION PATENT APPLICATION FOR USE OF AD04 IN OPIOID DEPENDENCE AND ABUSE.  Full Article

Adial Pharmaceuticals Files For Offering Of 1.86 Mln Shares
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Adial Pharmaceuticals Inc ::ADIAL PHARMACEUTICALS INC FILES FOR OFFERING OF 1.86 MILLION SHARES OF COMMON STOCK AND WARRANT TO PURCHASE 1.39 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Bankole Johnson Reports 22.3 Pct Stake In Adial Pharma
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Adial Pharmaceuticals Inc ::BANKOLE A. JOHNSON REPORTS A 22.3 PERCENT STAKE IN ADIAL PHARMACEUTICALS INC AS OF NOV 12 - SEC FILING.  Full Article

BRIEF-Adial Pharmaceuticals Announces Approval To Commence Landmark Onward!" Pivotal Phase 3 Trial In Poland

* ADIAL PHARMACEUTICALS ANNOUNCES APPROVAL TO COMMENCE LANDMARK ONWARD!" PIVOTAL PHASE 3 TRIAL IN POLAND